Belgian Promethera received approval to start World first Phase IIb/III stem-cell based urea cycle disorders treatment
Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It…
Promethera is a promising Belgian Biotechnology company developing stem-cell based treatment against liver diseases. It…
The average board of directors in the biotech world is roughly 90% male, and more…
DBV Technologies entered on the NASDAQ last Wednesday raising up to 90 million euros. It bets…
Janssen's Imbruvica (ibrutinib), the once-daily oral Bruton's tyrosine kinase (BTK) inhibitor, has been approved in Europe…
A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium…
The European Biotech Week was celebrated for the second time at the beggining of October.…
Today is Friday or Casual Day. Did you leave the suit and the tie at…
New Oncology announced that it has entered into a collaboration agreement with Gustave Roussy Cancer Campus,…
Bicycle Therapeutics, a next generation biotherapeutics UK-based company developing first-in-class bicyclic peptides, announced that it…
Rigontec GmbH, a German privately held biopharmaceutical company developing RNA-based immunotherapeutics for the treatment of…
Dutch biotech MIMETAS B.V. announces that it has raised 4 Million euros ($5.2M) to fund…
ARTES Biotechnology, InstrAction and Q-Biologicals establish a three-party consortium for vaccine developments for veterinary applications. Nowadays virus-like particles (VLPs)…